FinArc Investments Inc. Buys New Position in Amgen Inc. $AMGN

FinArc Investments Inc. bought a new stake in Amgen Inc. (NASDAQ:AMGN) in the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 10,150 shares of the medical research company’s stock, valued at approximately $3,571,000. Amgen comprises approximately 3.4% of FinArc Investments Inc.’s portfolio, making the stock its 7th biggest holding.

A number of other institutional investors and hedge funds also recently bought and sold shares of AMGN. High Note Wealth LLC increased its stake in Amgen by 5.8% during the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock worth $166,000 after buying an additional 28 shares during the period. TAGStone Capital Inc. boosted its position in Amgen by 0.7% in the 4th quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after buying an additional 28 shares during the period. Verus Capital Partners LLC grew its stake in shares of Amgen by 2.3% in the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock worth $403,000 after acquiring an additional 28 shares in the last quarter. Destination Wealth Management grew its stake in shares of Amgen by 2.1% in the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock worth $456,000 after acquiring an additional 29 shares in the last quarter. Finally, Breakwater Capital Group increased its position in shares of Amgen by 1.4% during the first quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company’s stock worth $717,000 after acquiring an additional 29 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on AMGN shares. BMO Capital Markets reiterated an “outperform” rating and issued a $400.00 price objective on shares of Amgen in a research note on Wednesday, July 1st. Truist Financial boosted their target price on Amgen from $327.00 to $340.00 and gave the stock a “hold” rating in a research note on Tuesday, July 7th. The Goldman Sachs Group set a $389.00 price target on Amgen in a report on Friday, June 5th. UBS Group increased their price target on Amgen from $400.00 to $420.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Finally, Guggenheim lifted their price objective on Amgen from $340.00 to $343.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Amgen currently has an average rating of “Hold” and an average target price of $357.00.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.85% of the company’s stock.

Amgen Stock Performance

Shares of AMGN stock opened at $387.64 on Friday. The company has a market cap of $209.21 billion, a P/E ratio of 26.98, a PEG ratio of 3.92 and a beta of 0.41. The firm has a fifty day moving average price of $355.69 and a 200 day moving average price of $353.55. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $398.00.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the firm earned $4.90 earnings per share. Sell-side analysts predict that Amgen Inc. will post 22.31 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be issued a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.6%. Amgen’s dividend payout ratio is presently 70.15%.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: The European Medicines Agency’s CHMP issued a positive opinion supporting broader use of Amgen’s cholesterol drug Repatha in high-risk adults without a prior heart attack or stroke. The recommendation, based on Phase 3 data showing a significant reduction in major cardiovascular events, could expand Repatha’s addressable market in Europe pending final regulatory approval. Amgen Wins Backing In Europe For Broader Repatha Use
• Positive Sentiment: Amgen declared a quarterly dividend of $2.52 per share, payable September 11 to shareholders of record on August 21. The announcement reinforces the company’s income appeal and signals continued confidence in cash generation. Amgen Announces 2026 Third Quarter Dividend
• Positive Sentiment: Amgen’s experimental monthly weight-loss medicine has six Phase 3 trials underway. Success could give the company a significant entry point into the rapidly growing obesity-drug market and provide a long-term growth catalyst, although the program remains unproven. Amgen Weight-Loss Drug Pipeline
• Neutral Sentiment: Analysts are moderately optimistic after Amgen’s strong longer-term performance, but valuation assessments are mixed: discounted-cash-flow analysis indicates upside, while market multiples appear closer to fair value. Investors are also awaiting further detail on second-quarter operating metrics.
• Negative Sentiment: Barclays maintained an Equal Weight/Hold rating and raised its price target only to $360, below Amgen’s recent trading level. The target implies limited near-term upside and reflects caution after the stock’s sizable advance. Barclays Keeps Hold Rating on Amgen
• Negative Sentiment: Amgen’s obesity-drug ambitions face formidable competition from established Eli Lilly and Novo Nordisk products. Investors may remain cautious until clinical data demonstrate that Amgen’s candidate can compete on efficacy, safety, dosing convenience, and commercialization.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.